Sarcopenia vs body mass index (BMI) as a prognostic biomarker in patients with metastatic clear cell renal cell carcinoma (mCCRCC) in the era of first line immune checkpoint inhibitors (ICIs)

被引：0
|
作者：
La Course, Bryce Douglas
Orcutt, Delaney
Gross, Evan
Fintelmann, Florian J.
Master, Viraj A.
Hall, Evan Thomas
Wrobel, Maria Marta
Psutka, Sarah P.
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Vanderbilt Univ, Nashville, TN USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Div Thorac Imaging & Intervent, Boston, MA USA
[4] Emory Univ, Atlanta, GA USA
[5] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[6] Ludwig Maximilians Univ Munchen, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16515
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
    Jo, Hyunji
    Hong, Joohyun
    Kim, Hongsik
    Kim, Hye Ryeon
    Kwon, Ghee Young
    Kang, Kyung A.
    Park, Sung Yoon
    Kim, Chan Kyo
    Park, Byung Kwan
    Chung, Jae Hoon
    Song, Wan
    Kang, Minyong
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Park, Se Hoon
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Sex and the clinical value of body mass index in patients with clear cell renal cell carcinoma
    Y Ohno
    J Nakashima
    Y Nakagami
    N Satake
    T Gondo
    M Ohori
    T Hatano
    M Tachibana
    British Journal of Cancer, 2013, 109 : 1899 - 1903
  • [43] Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Fu-Ming, C.
    Hsieh, C-Y.
    Wang, T-H.
    Tsai, M-H.
    Hua, C-H.
    Tang, C-H.
    Hsieh, C-H.
    Lien, M-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S667 - S667
  • [44] Sex and the clinical value of body mass index in patients with clear cell renal cell carcinoma
    Ohno, Y.
    Nakashima, J.
    Nakagami, Y.
    Satake, N.
    Gondo, T.
    Ohori, M.
    Hatano, T.
    Tachibana, M.
    BRITISH JOURNAL OF CANCER, 2013, 109 (07) : 1899 - 1903
  • [45] Outcomes and prognostic factors of first-line combination of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in TFE3-rearranged renal cell carcinoma.
    Zhao, Junjie
    Tang, Yanfeng
    Hu, Xu
    Chen, Junru
    Liu, Haoyang
    Liu, Haolin
    Liang, Jiayu
    Zhang, Xingming
    Zhao, Jinge
    Shen, Pengfei
    Liu, Zhenhua
    Sun, Guangxi
    Zeng, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 429 - 429
  • [46] Inflammatory markers to predict prognosis in renal cell carcinoma (RCC) patients treated with immune checkpoint inhibitors (ICIs)
    Carril, Lucia
    De Liano Lista, Alfonso Gomez
    Pozas, Javier
    Gordoa, Teresa Alonso
    Bernardini, Alejandra
    Carretero-Gonzalez, Alberto
    Martin Soberon, Maria Cruz
    Sepulveda Sanchez, Juan Manuel Manuel
    Paramio, Jesus
    Castellano, Daniel
    De Velasco, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [47] Peripheral blood cell counts as biomarkers of clinical benefit in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) receiving immune checkpoint inhibitor (ICI) combination (combo) therapies
    Nathani, Kaizen
    Touma, Amina
    Elias, Roy
    Pallauf, Maximilian
    Markowski, Mark Christopher
    Carducci, Michael Anthony
    Singla, Nirmish
    Ged, Yasser
    Ged, Yasser
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 446 - 446
  • [48] Immune checkpoint inhibitors plus tyrosine kinase inhibitors combination in the first-line setting of metastatic clear cell renal cell carcinoma: A meta-analysis of randomized clinical trials
    Martin Soberon, Maria Cruz
    Carretero-Gonzalez, Alberto
    de Velasco, Guillermo
    Carril, Lucia
    Castellano, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [49] BODY COMPOSITION MAY BE PROGNOSTIC AND PREDICTIVE OF CLINICAL OUTCOMES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
    Martini, Dylan
    Olsen, T. Anders
    Goyal, Subir
    Liu, Yuan
    Evans, Sean
    Magod, Benjamin
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Harris, Wayne
    Kucuk, Omer
    Carthon, Bradley
    Master, Viraj
    Bilen, Mehmet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A26 - A27
  • [50] Comparison of Outcomes Between African American and European American Patients With Metastatic Clear Cell Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors
    Kaur, Jasmeet
    Hasler, Jill S.
    Handorf, Elizabeth A.
    Zibelman, Matthew R.
    Anari, Fern
    Geynisman, Daniel M.
    Ghatalia, Pooja
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
12345